Form 4 Filing for Enliven Therapeutics, Inc.

This filing details a transaction by Lyssikatos Joseph P, Chief Scientific Officer of Enliven Therapeutics, Inc. On December 19, 2025, Mr. Lyssikatos sold 5,000 shares of Common Stock at a weighted average price of $16.8412 per share, pursuant to a Rule 10b5-1 trading plan. This sale was executed through multiple trades with prices ranging from $16.605 to $17.115. Following this transaction, Mr. Lyssikatos directly owns 897,688 shares. The shares are held in The Lyssikatos Revocable Trust 12/15/2011, for which Mr. Lyssikatos serves as trustee. The filing was signed by Ben Hohl, by power of attorney, on December 23, 2025.